Most U.S. hedge funds aren't expecting another big stock market sell-off as more firms curb bets on volatility, according to Nomura.Marketsread more
More tit-for-tat tariffs in the U.S.-China trade war could set the global economy up for a recession, according to Morgan Stanley.Marketsread more
A sell-off in chip stocks intensified following a report that chipmakers are cutting ties with Huawei after the Trump administration's ban.Marketsread more
A series of tweets Monday marked the latest chapter in Trump's decadeslong effort to refute published reports that his previous financial problems have rendered him an...Politicsread more
President Trump stands a chance of creating a new economic world order in his China trade fight, says the chief economic advisor of Allianz.Economyread more
Sens. Mitch McConnell and Tim Kaine plan to introduce a bill Monday that would raise the minimum age to buy tobacco to 21 in hopes of curbing what regulators are calling an...Health and Scienceread more
Ford Motor said Monday that it is laying off about 7,000 salaried workers, about 10% of that global workforce, as part of a restructuring plan designed to save the No. 2...Autosread more
Silicon Valley argues that the public market investors focus too much on near-term profits — but investors have embraced money-losing biotech IPOs.Marketsread more
Restaurants are thinking outside the box to attract and retain talent. A report from TDn2K, a restaurant analytics firm, finds that employee vacancies are a major concern for...Restaurantsread more
Forty percent of customers will choose a center to shop at based solely on the food that's there, JLL found in a new study. And nearly 38% of people want healthy options when...Retailread more
Google announced Google Glass Enterprise Edition 2 on Monday, a new set of smart glasses that's catered toward businesses and costs $999. Google has focused on business use...Technologyread more
(Adds details, background, shares)
Dec 19 (Reuters) - Drugmaker Eli Lilly and Co on Wednesday forecast 2019 revenue and adjusted profit above analysts' expectations, citing higher demand for newer medicines including diabetes drug Trulicity and psoriasis drug Taltz.
Trulicity, which recently overtook Humalog as Lilly's top-selling medicine, had sales of $816.2 million and helped power Lilly's profit beat in the third quarter.
The company forecast 2019 adjusted profit of $5.90 to $6 per share, compared with average analysts' estimates of $5.82 per share, according to IBES data from Refinitv.
Lilly said revenue was expected to be between $25.3 billion and $25.8 billion for the coming year, also above analysts' expectations of $24.43 billion.
However, the drugmaker said sales of erectile dysfunction drug Cialis will take a hit due to loss of patent exclusivity.
The Indianapolis-based company also reiterated its forecast for 2018 adjusted profit.
Shares of the drugmaker, which raised its quarterly dividend by 15 percent, were up 1 pct at $107.60 in light premarket trading. (Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)